LUOXIN PHARMACEUTICALS GROUP STOCK CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.21 CNY | -0.24% |
|
+7.95% | -21.46% |
| Sales 2021 | 6.48B 894M | Sales 2022 | 3.59B 495M | Capitalization | 8.34B 1.15B |
|---|---|---|---|---|---|
| Net income 2021 | 406M 56.03M | Net income 2022 | -1.23B -169M | EV / Sales 2021 | 2.47 x |
| Net Debt 2021 | 823M 114M | Net Debt 2022 | 2.17B 300M | EV / Sales 2022 | 2.93 x |
| P/E ratio 2021 |
37
x | P/E ratio 2022 |
-8.92
x | Employees | 4,582 |
| Yield 2021 |
0.29% | Yield 2022 |
-
| Free-Float | 55.27% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.24% | ||
| 1 week | +7.95% | ||
| Current month | -8.48% | ||
| 1 month | -9.85% | ||
| 3 months | -11.18% | ||
| 6 months | -19.66% | ||
| Current year | -21.46% |
1 week
3.97
4.33
1 month
3.904.73
Current year
3.415.80
1 year
3.417.26
3 years
3.4111.45
5 years
3.4118.89
10 years
3.4118.89
| Managers | Title | Age | Since |
|---|---|---|---|
Zhen Teng Liu
CEO | Chief Executive Officer | 38 | 20-04-22 |
Xian Chen
DFI | Director of Finance/CFO | 41 | 21-07-07 |
Hong Yan Liu
BRD | Director/Board Member | 42 | 23-01-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Feng Sheng Han
SEC | Corporate Secretary | 49 | 20-04-22 |
Liang Wei Song
CHM | Chairman | 44 | 23-01-30 |
Yun Pei Guo
BRD | Director/Board Member | 76 | 21-05-18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 4.21 | -0.24% | 6 845 830 |
| 24-04-23 | 4.22 | +3.94% | 13,130,550 |
| 24-04-22 | 4.06 | +0.50% | 5,204,900 |
| 24-04-19 | 4.04 | -1.70% | 6,767,838 |
| 24-04-18 | 4.11 | +0.24% | 18,308,510 |
End-of-day quote Shenzhen S.E., April 23, 2024
More quotes
Luoxin Pharmaceuticals Group Stock Co Ltd, formerly Zhejiang Doyin Pump Industry Co Ltd, is a China-based company mainly engaged in the research and development, manufacturing and sales of pharmaceutical products. The Company operates two segments. The Pharmaceutical Industry segment is engaged in the research and development, manufacturing and sales of chemical drug preparations and raw and auxiliary drugs. Its main products are digestive drugs, respiratory drugs and antibiotic drugs, among others. The Pharmaceutical Business segment is engaged in the sales and logistics of agent drugs and medical devices. The Company conducts its businesses in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-04-26
- Q4 2023 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -21.46% | 633M | |
| +25.61% | 672B | |
| +25.87% | 570B | |
| -5.24% | 360B | |
| +16.49% | 321B | |
| +8.28% | 300B | |
| +7.09% | 217B | |
| -9.12% | 204B | |
| +5.01% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- 002793 Stock
